118 results on '"Dienstmann, R."'
Search Results
2. ESMO Recommendations on clinical reporting of genomic test results for solid cancers
3. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
4. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
5. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
6. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer
7. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network
8. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
9. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
10. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
11. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2
12. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
13. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
14. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
15. 43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
16. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial
17. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
18. 160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC)
19. O-024 Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy
20. 2314P Quality and safety of research biopsies (RB) in oncology clinical trials
21. 2008P Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
22. 2193P Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
23. 2144P The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
24. 206P WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
25. 176P Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models
26. 1650P Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
27. 503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights
28. 1552P Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
29. 1637P Impact of immune-related adverse events (irAEs) and survival (OS) in a cohort of MPM patients (p) treated with immunotherapy (IT)
30. 1557MO Phase II trial evaluating effect of gonyautoxins (GTX), a paralytic shellfish poisoning (PSP) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)
31. 702P Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs)
32. 686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
33. 290P Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)
34. 211P Assessment of the financial toxicity after oncological treatment in patients with breast cancer in private oncological reference institutions in Brazil
35. 1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)
36. 1697TiP Evaluation of gonyautoxins (GTX) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)
37. 1577P Early mortality linked to COVID-19 in cancer patients as compared to historical control in pre-pandemic times
38. 461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR)
39. 445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor
40. 426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
41. LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors
42. P-47 5-fluorouracil bolus use in infusional regimens among oncologists: A survey by Brazilian Group of Gastrointestinal Tumors
43. 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer
44. 2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
45. Time to start testing KRAS and BRAF V600E mutations in stage III colon cancer? Not in routine care, yet in clinical trials
46. 35P Toxicity and safety of novel immuno-oncology (IO) treatments after prior immune checkpoint inhibitors (ICIs) exposure
47. 438P Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
48. 1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations
49. 1549P Molecular alterations (MA) with potential therapeutic implications in KRAS wild-type (WT) pancreatic cancer patients
50. 1545P DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.